A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer.
Contact: DESTINY-Ov01@anzgog.org.au





